Genome British Columbia has appointed Roshini Moodley Naidoo as its new president and CEO, effective Nov. 2.
Naidoo brings experience in health care, global non-profits, financial services and academia into the role, including more than a decade in senior executive roles at Discovery Health, a South African health-care organization, according to the organization that supports genomics research and innovation in B.C.
“She has led ambitious change in complex, highly regulated environments,” said Genome BC in a Thursday statement.
“She brings visionary strategic leadership and a deep belief in strong teams, agile and creative workplaces and a collaborative, outcomes-driven culture.”
Naidoo also worked at Oxfam America, where she developed partnerships between businesses and non-profits, and served as a professor of practice at Arizona State University’s College of Health Solutions and a senior fellow at Harvard Kennedy School’s Mossavar-Rahmani Center for Business and Government.
She holds a medical degree from the University of KwaZulu-Natal, a master of public health from Harvard T.H. Chan School of Public Health and an MBA from Harvard Business School.
Naidoo will succeed interim president and CEO Tony Brooks, who has held the position after former president and CEO Suzanne Gill stepped down in September 2025.
Brooks will return to his roles as chief financial officer and vice-president of entrepreneurship and commercialization, where he will continue to oversee financial and commercialization strategy, according to Genome BC.
